Comparative in-vitro anti-inflammatory, anticholinesterase and antidiabetic evaluation: computational and kinetic assessment of succinimides cyano-acetate derivatives
- 4 May 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (15) , 6935-6948
Abstract
This research was planned to synthesize cyano-acetate derivatives of succinimide and evaluate its comparative biological efficacy as anti-inflammatory, anti-cholinesterase and anti-diabetic, which was further validated by molecular docking studies. The three cyano-acetate derivatives of succinimide including compound 23 Methyl 2-cyano-2-(2,5-dioxopyrrolidin-3-yl)acetate, compound 31 Methyl 2-cyano-2-(1-methyl-2,5-dioxopyrrolidin-3-yl)acetate and compound 44 Methyl 2-cyano-2-(1-ethyl-2,5-dioxopyrrolidin-3-yl) acetate were synthesized. The mentioned compounds were checked for in vitro anti-inflammatory, anti-cholinesterase and anti-diabetic (α-amylase inhibition) activity. To validate the in vitro results, computational studies were carried out using molecular operating environment to analyse the BE, i.e. binding energies of all synthesized compounds against the respective enzymes. The Compounds 23, 31, 44 exhibited anti-inflammatory via inhibiting COX-2 (IC50 value of 204.08, 68.60 and 50.93 µM, respectively), COX-1 (IC50 value of 287, 185, and 143 µM, respectively) and 5-LOX (IC50 value of 138, 50.76 and 20, 87 µM respectively). They exhibited choline-mimetic potential, such as compound 23, 31 and 44 inhibited AChE enzyme (IC50 value of 240, 174, and 134 µM, respectively) and BChE enzyme (IC50 value of 203, 134 and 97 µM, respectively). The Compounds 23, 31, 44 exhibited anti-diabetic effect via inhibiting α-amylase enzyme (IC50 values of 250, 106 and 60 µM, respectively). Molecular docking studies revealed that the synthesized compounds have good binding affinity in the binding pockets of AChE, BChE, COX-2, 5-LOX and α-amylase enzyme and showed high binding energies. The synthesized succinimide derivatives, i.e. compound 23, 31, 44 showed marked inhibitory activities against cyclooxygenase, lipoxygenase, α-amylase and cholinesterase enzymes. Among these three, compound 44 and 31 showed strong anti-inflammatory and anti-diabetic activity while they displayed moderate anti-cholinesterase activity supported by molecular docking results. Communicated by Ramaswamy H. SarmaKeywords
This publication has 44 references indexed in Scilit:
- Evaluation of the inhibition of carbohydrate hydrolysing enzymes, antioxidant activity and polyphenolic content of extracts of ten African Ficus species (Moraceae) used traditionally to treat diabetesBMC Complementary and Alternative Medicine, 2013
- Analysis of chemical constituents and antinociceptive potential of essential oil of Teucrium Stocksianum bioss collected from the North West of PakistanBMC Complementary and Alternative Medicine, 2012
- Current and future treatments for Alzheimer’s diseaseTherapeutic Advances in Neurological Disorders, 2012
- Noncovalent Bifunctional Organocatalysts: Powerful Tools for Contiguous Quaternary‐Tertiary Stereogenic Carbon Formation, Scope, and Origin of EnantioselectivityChemistry – A European Journal, 2012
- Assessment of Anticholinesterase Activity ofGelidiella acerosa: Implications for Its Therapeutic Potential against Alzheimer’s DiseaseEvidence-Based Complementary and Alternative Medicine, 2012
- α-glucosidase inhibitors from plants: A natural approach to treat diabetesPharmacognosy Reviews, 2011
- The antinociceptive activity of Polygonatum verticillatum rhizomes in pain modelsJournal of Ethnopharmacology, 2010
- Antidiabetic activity of N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamidesBioorganic & Medicinal Chemistry Letters, 2008
- Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholineNeuroscience, 2002
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961